associated with OSA, SWD, or narcolepsy, while patients in the other study were new to treatment.50,51 These studies enrolled a total of 1071 patients and confirmed that headache is the most prevalent adverse event experienced when taking armodafinil (reported by 25% and 17% of armodafinil-treated patients in the two trials).50,51 Nasopharyngitis and insomnia were experienced by 17% and 14% of ar